Mild Cognitive Impairment - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Mild Cognitive Impairment - Pipeline Review, H1 2016', provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment - The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects - The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Mild Cognitive Impairment Overview 10 Therapeutics Development 11 Pipeline Products for Mild Cognitive Impairment - Overview 11 Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 12 Mild Cognitive Impairment - Therapeutics under Development by Companies 13 Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 14 Mild Cognitive Impairment - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Mild Cognitive Impairment - Products under Development by Companies 18 Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 20 Mild Cognitive Impairment - Companies Involved in Therapeutics Development 21 AbbVie Inc. 21 AgeneBio Inc. 22 Avraham Pharmaceuticals Ltd. 23 CereSpir Incorporated 24 D-Pharm Ltd. 25 Eisai Co., Ltd. 26 Eli Lilly and Company 27 Ensol Biosciences Inc. 28 Genzyme Corporation 29 Nanotherapeutics, Inc. 30 Neuron Biopharma SA 31 Octapharma AG 32 Sage Therapeutics, Inc. 33 Suven Life Sciences Ltd. 34 Takeda Pharmaceutical Company Limited 35 Therapix Biosciences Ltd 36 Mild Cognitive Impairment - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 ABT-957 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BAN-2401 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CSP-1103 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 DAOI-B - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 DP-NDD - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 dronabinol - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 immune globulin (human) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ladostigil tartrate - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 levetiracetam - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LY-2599666 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 LY-3002813 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Moriah-1000 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NPS-0158 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NSP-0163 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 NST-0037 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 NST-0076 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 NST-0078 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NTC-942 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 pioglitazone hydrochloride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 sargramostim - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 sepranolone - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SUVN-501 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 SUVN-502 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SUVN-507 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SUVN-512 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 SUVN-976 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 tropisetron hydrochloride - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Mild Cognitive Impairment - Recent Pipeline Updates 84 Mild Cognitive Impairment - Dormant Projects 98 Mild Cognitive Impairment - Discontinued Products 100 Mild Cognitive Impairment - Product Development Milestones 101 Featured News & Press Releases 101 Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment 101 Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102 Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102 Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 103 Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 103 May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 105 Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m 105 Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria. 105 Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 106 Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 107 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 108 Disclaimer 109
List of Tables
Number of Products under Development for Mild Cognitive Impairment, H1 2016 11 Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Mild Cognitive Impairment - Pipeline by AbbVie Inc., H1 2016 21 Mild Cognitive Impairment - Pipeline by AgeneBio Inc., H1 2016 22 Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H1 2016 23 Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H1 2016 24 Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H1 2016 25 Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H1 2016 26 Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2016 27 Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H1 2016 28 Mild Cognitive Impairment - Pipeline by Genzyme Corporation, H1 2016 29 Mild Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H1 2016 30 Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2016 31 Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2016 32 Mild Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H1 2016 33 Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H1 2016 34 Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 35 Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H1 2016 84 Mild Cognitive Impairment - Dormant Projects, H1 2016 98 Mild Cognitive Impairment - Dormant Projects (Contd..1), H1 2016 99 Mild Cognitive Impairment - Discontinued Products, H1 2016 100
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.